Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Phase 3

Completed

Conditions: Melanoma

Interventions: Biological: Spartalizumab
Other: Placebo
Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2016-11-18

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 573

Registration Number: NCT02967692

Locations: 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 15 locations

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Phase 2

Completed

Conditions: Post-Essential Thrombocythemia Myelofibrosis
Primary Myelofibrosis
Post-Polycythemia Vera-Myelofibrosis

Interventions: Drug: ruxolitinib

First Posted Date: 2016-11-17

Last Posted Date: 2020-04-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT02966353

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Phase 2

Completed

Conditions: Primary Sjogren Syndrome

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2016-11-15

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 190

Registration Number: NCT02962895

Locations: 🇺🇸
Indiana Univ School of Dentistry, Indianapolis, Indiana, United States
🇺🇸
The John Hopkins Jerome L Greene Sjogren, Baltimore, Maryland, United States
🇺🇸
Tufts School of Dental Medicine, Boston, Massachusetts, United States

and more 7 locations

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 3

Active, not recruiting

Conditions: Tuberous Sclerosis Complex

Interventions: Drug: everolimus

First Posted Date: 2016-11-11

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT02962414

Locations: 🇺🇸
TGen APNNA, Phoenix, Arizona, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
UCSF Benioff Children s Hospital, Oakland, California, United States

and more 12 locations

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Placebo
Drug: ACZ885

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT02961218

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Phase 2

Completed

Conditions: Postoperative Ocular Pain After PRK Surgery

Interventions: Drug: SAF312
Drug: Placebo

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02961062

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2016-11-06

Last Posted Date: 2021-08-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1009

Registration Number: NCT02957409

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 2

Completed

Conditions: Well-differentiated Non-functional NET of Thoracic Origin
Well-differentiated Non-functional NET of Gastrointestinal Origin
Well-differentiated Non-functional NET of Pancreatic Origin
Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions: Drug: PDR001

First Posted Date: 2016-11-04

Last Posted Date: 2021-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT02955069

Locations: 🇺🇸
Rocky Mountain Cancer Centers SC-2, Denver, Colorado, United States
🇺🇸
University of TX MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 5 locations

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety

Phase 4

Completed

Conditions: Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Interventions: Biological: Ranibizumab
Radiation: Grid&Direct short pulse laser photocoagulation

First Posted Date: 2016-11-03

Last Posted Date: 2020-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT02953938

Locations: 🇯🇵
Novartis Investigative Site, Hokkaido, Japan

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Epithelial Ovarian Cancer
Renal Cell Carcinoma

Interventions: Drug: HKT288

First Posted Date: 2016-10-27

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT02947152

Locations: 🇨🇭
Novartis Investigative Site, Locarno, Switzerland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy